Ensayos clínicos

8.676 ensayos encontrados

SuspendidoRENIS

Estudio doble ciego, controlado con placebo, aleatorizado, de grupos paralelos, de 12 meses de duración sobre la seguridad y eficacia de leucometiltioninio bis (hidrometanosulfonato) en pacientes con Demencia Frontotemporal Variante Conductual (DFTvc).

INTERVENTIONALID: IS000619

CompletadoRENIS

H6D-MC-LVJJ: Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo de tadalafilo para distrofia muscular de Duchenne.

INTERVENTIONALID: IS000605

CompletadoRENIS

Eficacia y seguridad de 3 dosis de S 38093 (2, 5 y 20 mg/día) frente a placebo, en co-administración con donepezilo (10 mg/día) en pacientes con Enfermedad de Alzheimer moderada Estudio internacional de fase IIb, de 24 semanas, multicéntrico, aleatorizado, doble ciego, controlado con placebo.

INTERVENTIONALID: IS000376

CompletadoRENIS

Estudio prospectivo para comparar la eficacia y seguridad de masitinib versus placebo en el tratamiento de pacientes con esclerosis lateral amiotrófica (ELA)

INTERVENTIONALID: IS000340

CompletadoRENIS

WN25203-Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, de dos años de duración, para evaluar el efecto de RO4909832 subcutáneo en la cognición y el funcionamiento en la enfermedad de Alzheimer Prodrómica con opción a dos años de tratamiento adicional.

INTERVENTIONALID: IS000291

Activo, no reclutaRENIS

Estudio Observacional de Casos y Controles para Evaluar la Frecuencia de Crisis y los Eventos Adversos Producidos en Pacientes Medicados con Drogas Antiepilépticas Similares y Genéricas Vs Aquellos Medicados con Drogas Antiepilépticas Originales en un Hospital de la República Argentina

OBSERVATIONALID: IS000150

Activo, no reclutaRENIS

A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults

INTERVENTIONALInicio: 21 de jul de 2016ID: NCT02831673

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

INTERVENTIONALInicio: 1 de dic de 2025ID: NCT07241390

DesconocidoClinicalTrials.gov

Looking For Genetic and Environmental Risk Factors and Therapeutic Aspects in Cervical Artery Dissections

OBSERVATIONALInicio: 1 de jul de 2005ID: NCT00657969

CompletadoFase 3ClinicalTrials.gov

A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared With Levetiracetam as Monotherapy in Pediatric Subjects With New or Recent-Onset Epilepsy

INTERVENTIONALInicio: 6 de oct de 2014ID: NCT02201251

CompletadoClinicalTrials.gov

Predicting Factors for Depression in Patients With MS in Argentina

OBSERVATIONALInicio: 1 de ago de 2008ID: NCT01079975

CompletadoFase 3ClinicalTrials.gov

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy >=1 Month to <4 Years of Age With Partial-Onset Seizures

INTERVENTIONALInicio: 5 de jun de 2015ID: NCT02477839

CompletadoFase 3ClinicalTrials.gov

A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures

INTERVENTIONALInicio: 29 de abr de 2013ID: NCT01713946

TerminadoFase 3ClinicalTrials.gov

An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's Disease

INTERVENTIONALInicio: 22 de may de 2020ID: NCT04339413

TerminadoFase 3ClinicalTrials.gov

Multinational, Randomized, Double Blind, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 800 mg od Versus 10 Days Penicillin V 500 mg Tid in Adolescent and Adult Subjects Equal to or Over 13 Years With Streptococcus Pyogenes Tonsillitis/Pharyngitis

INTERVENTIONALInicio: 1 de feb de 2006ID: NCT00315549

CompletadoFase 3ClinicalTrials.gov

Phase III, Open-label, Switch Over Trial of the Efficacy and Safety of Agalsidase Beta Biosidus (AGA BETA BS) in Fabry Disease Patients Previously Stabilized With Fabrazyme®

INTERVENTIONALInicio: 13 de dic de 2022ID: NCT05843916

Ensayos clínicos

Estudio doble ciego, controlado con placebo, aleatorizado, de grupos paralelos, de 12 meses de duración sobre la seguridad y eficacia de leucometiltioninio bis (hidrometanosulfonato) en pacientes con Demencia Frontotemporal Variante Conductual (DFTvc).

H6D-MC-LVJJ: Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo de tadalafilo para distrofia muscular de Duchenne.

Eficacia y seguridad de 3 dosis de S 38093 (2, 5 y 20 mg/día) frente a placebo, en co-administración con donepezilo (10 mg/día) en pacientes con Enfermedad de Alzheimer moderada Estudio internacional de fase IIb, de 24 semanas, multicéntrico, aleatorizado, doble ciego, controlado con placebo.

Estudio prospectivo para comparar la eficacia y seguridad de masitinib versus placebo en el tratamiento de pacientes con esclerosis lateral amiotrófica (ELA)

Estudio Observacional de Casos y Controles para Evaluar la Frecuencia de Crisis y los Eventos Adversos Producidos en Pacientes Medicados con Drogas Antiepilépticas Similares y Genéricas Vs Aquellos Medicados con Drogas Antiepilépticas Originales en un Hospital de la República Argentina

ADNI II

DMD 114349

18F-Fdopa PET en Enfermedad de Parkinson

DMD114044

A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

Looking For Genetic and Environmental Risk Factors and Therapeutic Aspects in Cervical Artery Dissections

A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared With Levetiracetam as Monotherapy in Pediatric Subjects With New or Recent-Onset Epilepsy

Predicting Factors for Depression in Patients With MS in Argentina

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy >=1 Month to <4 Years of Age With Partial-Onset Seizures

A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures

An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's Disease

Multinational, Randomized, Double Blind, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 800 mg od Versus 10 Days Penicillin V 500 mg Tid in Adolescent and Adult Subjects Equal to or Over 13 Years With Streptococcus Pyogenes Tonsillitis/Pharyngitis

Phase III, Open-label, Switch Over Trial of the Efficacy and Safety of Agalsidase Beta Biosidus (AGA BETA BS) in Fabry Disease Patients Previously Stabilized With Fabrazyme®